Mark Anderson, PhD
Dr. Mark Anderson is a cancer biologist and drug developer with over 25 years of experience in the biotechnology and pharmaceutical industries. He has led drug discovery teams focused on the preclinical development of biologically based therapeutics for cancer and has advanced multiple novel agents from discovery to clinical testing. He received his Ph.D. in Biological Chemistry from the University of Michigan in Ann Arbor and conducted his postdoctoral training at Merck Research Laboratories in West Point, Pennsylvania.
Dr. Anderson spent several years in the biotechnology industry discovering and developing innate immune stimulants and anti-cancer agents at Magainin Pharmaceuticals, followed by 15 years at Johnson & Johnson leading teams developing anti-cancer biologics, most recently as Scientific Director of Oncology Research at Janssen Pharmaceuticals. He has published numerous peer-reviewed journal articles, book chapters, and patents in the areas of transcriptional control, innate immunity, cancer biology, and biologic cancer therapeutics. Dr. Anderson’s expertise includes strategic R&D and business planning, the technical development of antibodies, antibody drug conjugates, novel biologic scaffolds, immuno-oncology agents, and bispecific antibodies for the treatment of cancer.